48.36
0.32 (0.67%)
| Previous Close | 48.04 |
| Open | 48.00 |
| Volume | 303,183 |
| Avg. Volume (3M) | 737,141 |
| Market Cap | 3,437,163,520 |
| Price / Book | 2.36 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Diluted EPS (TTM) | -2.58 |
| Total Debt/Equity (MRQ) | 0.92% |
| Current Ratio (MRQ) | 23.29 |
| Operating Cash Flow (TTM) | -134.78 M |
| Levered Free Cash Flow (TTM) | -80.30 M |
| Return on Assets (TTM) | -17.24% |
| Return on Equity (TTM) | -22.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Structure Therapeutics Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 3.08% |
| % Held by Institutions | 101.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 31 Mar 2026 | 6,555,555 |
| Casdin Capital, Llc | 31 Mar 2026 | 1,175,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jun 2026 | CNBC | Drugmakers race to find a place in the next wave of obesity drugs |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |